Make the launch decision from documented evidence
Record each significant finding, the change made, and the evidence from retesting. Assign an owner to unresolved issues and distinguish those that prevent the offer from being delivered from improvements that can follow through an appropriate process.
Review marketing against the verified scope. Apply MHRA medicines-advertising guidance to treatment-related promotion, and avoid claims that a successful rehearsal guarantees clinical outcomes or treatment. Describe only the capabilities and arrangements the service can actually support. MHRA: advertise your medicines
Start the Telford pilot within those boundaries and continue examining complete episodes. A safe sample exercise provides useful readiness evidence, but real use can reveal access, communication, or workload issues that the test set did not anticipate.
Retest the relevant pathways after changes to software, suppliers, staffing, or clinical scope. Preserve an honest account of simulations and unavailable integrations. The strongest launch record shows what worked, what was fixed, and what remains limited, rather than presenting a single green technical check as proof of a complete clinical service.